Texas Permanent School Fund Corp Sells 16,321 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Texas Permanent School Fund Corp trimmed its holdings in Exelixis, Inc. (NASDAQ:EXELFree Report) by 5.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 270,398 shares of the biotechnology company’s stock after selling 16,321 shares during the quarter. Texas Permanent School Fund Corp owned about 0.09% of Exelixis worth $5,908,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fifth Third Bancorp lifted its stake in shares of Exelixis by 100.9% in the 2nd quarter. Fifth Third Bancorp now owns 1,366 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 686 shares during the period. Massmutual Trust Co. FSB ADV increased its position in Exelixis by 189.7% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 1,440 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 943 shares in the last quarter. Covestor Ltd increased its position in Exelixis by 245.6% in the 1st quarter. Covestor Ltd now owns 1,676 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 1,191 shares in the last quarter. Denali Advisors LLC increased its position in Exelixis by 7,995.2% in the 3rd quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 1,679 shares in the last quarter. Finally, CENTRAL TRUST Co bought a new stake in Exelixis in the 2nd quarter valued at about $34,000. 93.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of research analyst reports. Stifel Nicolaus boosted their target price on Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. Morgan Stanley boosted their target price on Exelixis from $22.00 to $23.00 and gave the company an “equal weight” rating in a research report on Thursday, November 2nd. BTIG Research began coverage on Exelixis in a research report on Tuesday, December 19th. They issued a “buy” rating and a $27.00 target price for the company. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Friday, January 26th. Finally, Citigroup began coverage on Exelixis in a report on Friday, December 15th. They set a “buy” rating and a $31.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and an average price target of $25.94.

Check Out Our Latest Stock Report on Exelixis

Insider Activity at Exelixis

In related news, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $22.01, for a total value of $550,250.00. Following the transaction, the executive vice president now owns 583,345 shares in the company, valued at $12,839,423.45. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $22.01, for a total transaction of $550,250.00. Following the sale, the executive vice president now owns 583,345 shares in the company, valued at $12,839,423.45. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David Edward Johnson bought 120,409 shares of the company’s stock in a transaction on Monday, November 27th. The shares were bought at an average price of $21.61 per share, for a total transaction of $2,602,038.49. Following the transaction, the director now owns 910,730 shares of the company’s stock, valued at $19,680,875.30. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 114,149 shares of company stock worth $2,587,603. Insiders own 2.90% of the company’s stock.

Exelixis Trading Up 0.2 %

Exelixis stock opened at $20.22 on Monday. Exelixis, Inc. has a 12 month low of $16.15 and a 12 month high of $24.34. The business’s 50 day simple moving average is $22.65 and its 200 day simple moving average is $21.79. The company has a market cap of $6.13 billion, a price-to-earnings ratio of 31.59, a PEG ratio of 0.53 and a beta of 0.53.

Exelixis Company Profile

(Free Report)

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Read More

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXELFree Report).

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.